Read our Recent Headlines

February 22 Biotech Update

A little bit of news since yesterday and I will focus on them but more broadly the sector seemed to struggle yesterday. It had been outperforming so a day of.

February 21 Biotech Update

Long weekend and a significant lack of news. I do not think there was an expectation of big news but sometimes these long weekends can surprise with a flurry of.

February 17 Biotech Update

Some news to talk about today in a couple stocks and one idea I want to float that has been ruminating in my mind. The sector continues to do well.

Dave Trading – March 2017

*** David Sobek is a disciplined value investor.  Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.

February 15 Biotech Update

We have some additional news yesterday but nothing that is necessarily positive for the sector. It certainly rallied in the afternoon and I suspect there is enough juice left for.

February 14 Biotech Update

Some decent news this morning for the sector but not quite a robust reaction. Perhaps the sector needs to pause after its recent run or perhaps it will rally later.

February 13 Biotech Update

A relatively slow start to the week, so I will start off with perhaps the most (maybe only) meaningful fundamental news and then highlight another stock that is very likely.


Quick Facts














Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!